Phase 1 Study of StealthX™ vaccine
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Exosome multivalent vaccine Capricor Therapeutics (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 19 Mar 2025 According to a Capricor Therapeutics media release, National Institute of Allergy and Infectious Diseases (NIAID) is planning for regulatory approval in the second quarter of 2025 with the clinical study initiated soon thereafter
- 06 Mar 2024 New trial record
- 29 Feb 2024 According to a Capricor Therapeutics media release, NIAID plans to initiate the Phase 1 clinical trial in late 2024, subject to regulatory approval. If NIAID finds that our StealthX™ vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2.